High-dose-rate interstitial brachytherapy with hypoxic radiosensitizer KORTUC II for unresectable pelvic sidewall recurrence of uterine cervical cancer: a case report.
High-dose-rate interstitial brachytherapy with hypoxic radiosensitizer KORTUC II for unresectable pelvic sidewall recurrence of uterine cervical cancer: a case report.
复制标题
DOI：
10.5114/jcb.2020.101695
复制
发表时间：
2020-12
影响因子：
1.4
通讯作者：
Nihei K
中科院分区：
文献类型：
--
作者：
Nakata M;Yoshida K;Shimbo T;Yoshikawa N;Yoshioka H;Hori A;Sato C;Uesugi Y;Kogata Y;Masui K;Murakami N;Kashihara T;Akiyama H;Tselis N;Ohmichi M;Nihei K
为了改善不能切除的宫颈癌盆腔侧壁复发患者的放射治疗结果，我们将高剂量率组织间近距离放射治疗(HDR-ISBT)与新测试的低氧放射增敏剂Kochi Oxydol放射治疗(KORTUC II)相结合，KORTUC II是一种酶靶向放射增敏治疗，包括透明质酸钠和过氧化氢混合注射。我们报告一位63岁的子宫颈癌患者，在初次子宫切除后出现广泛的盆腔侧壁复发。肿瘤大小为55×25×80 mm，计算体积为89.7毫升。全盆腔照射50Gy25次，联合每周顺铂注射。KORTUC II注射分两次进行：第21天(42GY)和第24天(48GY)。全盆照射结束后，采用HDR-ISBT，25Gy5次，tid。给药3天以上。植入时同时注射KORTUC II。临床靶区剂量-体积直方图(DVH)值分别为D90、D98和D100，分别为6.0、5.0和3.5Gy次/次。膀胱、直肠、乙状结肠和小肠的D2cc值分别为2.1、4.1、3.2和2.0Gy4次/次。未观察到≥分级3级的急性不良事件。反复3级肾盂肾炎在治疗后11、24和26个月出现晚期并发症，并通过抗生素成功治愈。此外，还记录了2级晚期毒性，包括坐骨神经痛、下肢淋巴水肿和尿失禁。目前，在HDR-ISBT术后32个月，患者仍然没有疾病，身体状况也没有毒性相关的恶化。
In order to improve oncologic outcomes in radiotherapy treatments of patients with unresectable pelvic sidewall recurrences of uterine cervical cancer, we combined high-dose-rate interstitial brachytherapy (HDR-ISBT) with newly tested hypoxic radiosensitizer Kochi oxydol-radiation therapy for unresectable carcinomas (KORTUC II), an enzyme-targeting radiosensitization treatment involving intra-tumoral injection of sodium hyaluronate mixed with hydrogen peroxide. We report on a 63-year-old patient referred to our department with an extensive pelvic sidewall recurrence of uterine cervical cancer after initial hysterectomy. The tumor size was 55 × 25 × 80 mm, with a calculated volume of 89.7 cc. Whole pelvic irradiation of 50 Gy in 25 fractions was administered, combined with weekly cisplatin injections. KORTUC II injections were given two times: at day 21 (42 Gy) and at day 24 (48 Gy). After finishing whole pelvic irradiation, HDR-ISBT of 25 Gy in 5 fractions b.i.d. over 3 days was administered. KORTUC II was also injected at the time of implantation. Dose-volume histogram (DVH) values for clinical target volume were D90, D98, and D100 of 6.0, 5.0, and 3.5 Gy per fraction, respectively. D2cc values were 2.1, 4.1, 3.2, and 2.0 Gy per fraction for the bladder, rectum, sigmoid colon, and small bowel, respectively. No acute adverse events ≥ grade 3 were observed. Repeated grade 3 pyelonephritis occurred as a late complication at 11, 24, and 26 months after the treatment, and was successfully resolved with antibiotics. Moreover, grade 2 late toxicity was documented, including sciatic neuralgia, lower limb lymphedema, and urinary incontinence. At present, 32 months after HDR-ISBT, the patient remains free of disease, with no toxicity-related deterioration in physical condition.
登录
查看更多内容
影响因子：
50.5
作者：
Maneo, A;Landoni, F;Mangioni, C
通讯作者：
Mangioni, C
DOI：
10.1056/nejmoa1309748
发表时间：
2014-02-20
期刊：
The New England journal of medicine
影响因子：
--
作者：
Tewari KS;Sill MW;Long HJ 3rd;Penson RT;Huang H;Ramondetta LM;Landrum LM;Oaknin A;Reid TJ;Leitao MM;Michael HE;Monk BJ
通讯作者：
Monk BJ
影响因子：
5.2
作者：
Ogawa, Yasuhiro;Kubota, Kei;Sano, Shigetoshi
通讯作者：
Sano, Shigetoshi
影响因子：
1.9
作者：
Albuquerque, Kevin;Hrycushko, Brian A.;Yashar, Catherine
通讯作者：
Yashar, Catherine
DOI：
10.1097/igc.0000000000000028
发表时间：
2014-01-01
影响因子：
4.8
作者：
Mabuchi, Seiji;Takahashi, Ryoko;Kimura, Tadashi
通讯作者：
Kimura, Tadashi